Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
A Randomized Open-Label Phase 3 Trial of BMS-936558 (Nivolumab) Versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy
Status: Enrolling
Updated:  9/20/2017
University of Colorado
mi
from
Aurora, CO
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
A Randomized Open-Label Phase 3 Trial of BMS-936558 (Nivolumab) Versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy
Status: Enrolling
Updated: 9/20/2017
University of Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
A Randomized Open-Label Phase 3 Trial of BMS-936558 (Nivolumab) Versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy
Status: Enrolling
Updated:  9/20/2017
Mount Sinai Comprehensive Cancer Center
mi
from
Miami Beach, FL
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
A Randomized Open-Label Phase 3 Trial of BMS-936558 (Nivolumab) Versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy
Status: Enrolling
Updated: 9/20/2017
Mount Sinai Comprehensive Cancer Center
mi
from
Miami Beach, FL
Click here to add this to my saved trials
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
A Randomized Open-Label Phase 3 Trial of BMS-936558 (Nivolumab) Versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy
Status: Enrolling
Updated:  9/20/2017
University Hospitals
mi
from
Cleveland, OH
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
A Randomized Open-Label Phase 3 Trial of BMS-936558 (Nivolumab) Versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy
Status: Enrolling
Updated: 9/20/2017
University Hospitals
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
A Randomized Open-Label Phase 3 Trial of BMS-936558 (Nivolumab) Versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy
Status: Enrolling
Updated:  9/20/2017
St. Luke'S Health System
mi
from
Easton, PA
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
A Randomized Open-Label Phase 3 Trial of BMS-936558 (Nivolumab) Versus Investigator's Choice in Advanced (Unresectable or Metastatic) Melanoma Patients Progressing Post Anti-CTLA-4 Therapy
Status: Enrolling
Updated: 9/20/2017
St. Luke'S Health System
mi
from
Easton, PA
Click here to add this to my saved trials
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204)/Cobimetinib (GDC-0973) With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Status: Enrolling
Updated:  9/22/2017
The Angeles Clinic
mi
from
Los Angeles, CA
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204)/Cobimetinib (GDC-0973) With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Status: Enrolling
Updated: 9/22/2017
The Angeles Clinic
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204)/Cobimetinib (GDC-0973) With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Status: Enrolling
Updated:  9/22/2017
Harry and Jeannette Weinberg Cancer Institute at Franklin Square
mi
from
Baltimore, MD
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204)/Cobimetinib (GDC-0973) With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Status: Enrolling
Updated: 9/22/2017
Harry and Jeannette Weinberg Cancer Institute at Franklin Square
mi
from
Baltimore, MD
Click here to add this to my saved trials
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204)/Cobimetinib (GDC-0973) With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Status: Enrolling
Updated:  9/22/2017
Massachusetts General Hospital
mi
from
Boston, MA
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204)/Cobimetinib (GDC-0973) With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Status: Enrolling
Updated: 9/22/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204)/Cobimetinib (GDC-0973) With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Status: Enrolling
Updated:  9/22/2017
Beth Israel Deaconess Medical Center (BIDMC)
mi
from
Boston, MA
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204)/Cobimetinib (GDC-0973) With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Status: Enrolling
Updated: 9/22/2017
Beth Israel Deaconess Medical Center (BIDMC)
mi
from
Boston, MA
Click here to add this to my saved trials
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204)/Cobimetinib (GDC-0973) With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Status: Enrolling
Updated:  9/22/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204)/Cobimetinib (GDC-0973) With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Status: Enrolling
Updated: 9/22/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204)/Cobimetinib (GDC-0973) With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Status: Enrolling
Updated:  9/22/2017
NYU Clinical Cancer Center
mi
from
New York, NY
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204)/Cobimetinib (GDC-0973) With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Status: Enrolling
Updated: 9/22/2017
NYU Clinical Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204)/Cobimetinib (GDC-0973) With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Status: Enrolling
Updated:  9/22/2017
Columbia University Medical Center
mi
from
New York, NY
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204)/Cobimetinib (GDC-0973) With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Status: Enrolling
Updated: 9/22/2017
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204)/Cobimetinib (GDC-0973) With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Status: Enrolling
Updated:  9/22/2017
OSU Comprehensive Cancer Center
mi
from
Columbus, OH
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204)/Cobimetinib (GDC-0973) With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Status: Enrolling
Updated: 9/22/2017
OSU Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204)/Cobimetinib (GDC-0973) With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Status: Enrolling
Updated:  9/22/2017
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204)/Cobimetinib (GDC-0973) With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Status: Enrolling
Updated: 9/22/2017
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204)/Cobimetinib (GDC-0973) With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Status: Enrolling
Updated:  9/22/2017
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204)/Cobimetinib (GDC-0973) With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Status: Enrolling
Updated: 9/22/2017
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204)/Cobimetinib (GDC-0973) With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Status: Enrolling
Updated:  9/22/2017
University of Washington Medical Center
mi
from
Seattle, WA
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204)/Cobimetinib (GDC-0973) With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Status: Enrolling
Updated: 9/22/2017
University of Washington Medical Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204)/Cobimetinib (GDC-0973) With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Status: Enrolling
Updated:  9/22/2017
University of Colorado Cancer Center
mi
from
Aurora, CO
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204)/Cobimetinib (GDC-0973) With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Status: Enrolling
Updated: 9/22/2017
University of Colorado Cancer Center
mi
from
Aurora, CO
Click here to add this to my saved trials
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204)/Cobimetinib (GDC-0973) With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Status: Enrolling
Updated:  9/22/2017
Georgetown Lombardi Comprehensive Cancer Center
mi
from
Washington, D.C.,
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204)/Cobimetinib (GDC-0973) With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Status: Enrolling
Updated: 9/22/2017
Georgetown Lombardi Comprehensive Cancer Center
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204)/Cobimetinib (GDC-0973) With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Status: Enrolling
Updated:  9/22/2017
Washington Cancer Institute at MedStar Washington Hospital Center.
mi
from
Washington, D.C.,
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Randomized Phase II Trial of Vemurafenib (PLX4032/RG7204)/Cobimetinib (GDC-0973) With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma
Status: Enrolling
Updated: 9/22/2017
Washington Cancer Institute at MedStar Washington Hospital Center.
mi
from
Washington, D.C.,
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
Phase I Evaluation of Alpha-Type-1 DC-Based and cDC-Based Intralymphatic Vaccines in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  9/25/2017
UPMC Cancer Center at Magee-Womens Hospital
mi
from
Pittsburgh, PA
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
Phase I Evaluation of Alpha-Type-1 DC-Based and cDC-Based Intralymphatic Vaccines in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 9/25/2017
UPMC Cancer Center at Magee-Womens Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
Phase I Evaluation of Alpha-Type-1 DC-Based and cDC-Based Intralymphatic Vaccines in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  9/25/2017
UPMC Cancer Centers
mi
from
Pittsburgh, PA
Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma
Phase I Evaluation of Alpha-Type-1 DC-Based and cDC-Based Intralymphatic Vaccines in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 9/25/2017
UPMC Cancer Centers
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma
A Pilot Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Combination With Pembrolizumab PD-1 Inhibitor for Patients With Advanced Melanoma
Status: Enrolling
Updated:  9/26/2017
Mary Crowley Medical Research Centers
mi
from
Dallas, TX
Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma
A Pilot Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Combination With Pembrolizumab PD-1 Inhibitor for Patients With Advanced Melanoma
Status: Enrolling
Updated: 9/26/2017
Mary Crowley Medical Research Centers
mi
from
Dallas, TX
Click here to add this to my saved trials
Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma
A Pilot Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Combination With Pembrolizumab PD-1 Inhibitor for Patients With Advanced Melanoma
Status: Enrolling
Updated:  9/26/2017
Texas Oncology PA Texas Cancer Center
mi
from
Abilene, TX
Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma
A Pilot Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Combination With Pembrolizumab PD-1 Inhibitor for Patients With Advanced Melanoma
Status: Enrolling
Updated: 9/26/2017
Texas Oncology PA Texas Cancer Center
mi
from
Abilene, TX
Click here to add this to my saved trials
Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma
A Pilot Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Combination With Pembrolizumab PD-1 Inhibitor for Patients With Advanced Melanoma
Status: Enrolling
Updated:  9/26/2017
Cancer Care Northwest
mi
from
Spokane, WA
Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma
A Pilot Study of Vigil™ Augmented Autologous Tumor Cell Immunotherapy in Combination With Pembrolizumab PD-1 Inhibitor for Patients With Advanced Melanoma
Status: Enrolling
Updated: 9/26/2017
Cancer Care Northwest
mi
from
Spokane, WA
Click here to add this to my saved trials
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated:  10/4/2017
The Angeles Clinic & Research Institute
mi
from
Los Angeles, CA
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated: 10/4/2017
The Angeles Clinic & Research Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated:  10/4/2017
Sharp Memorial Hospital
mi
from
San Diego, CA
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated: 10/4/2017
Sharp Memorial Hospital
mi
from
San Diego, CA
Click here to add this to my saved trials
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated:  10/4/2017
California Pacific Medical Center
mi
from
San Francisco, CA
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated: 10/4/2017
California Pacific Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated:  10/4/2017
North. Cal. Melanoma Center-St. Mary's Medical Center
mi
from
San Francisco, CA
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated: 10/4/2017
North. Cal. Melanoma Center-St. Mary's Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated:  10/4/2017
Yale University School of Medicine
mi
from
New Haven, CT
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated: 10/4/2017
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated:  10/4/2017
Boca Raton Comprehensive Cancer Center
mi
from
Boca Raton, FL
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated: 10/4/2017
Boca Raton Comprehensive Cancer Center
mi
from
Boca Raton, FL
Click here to add this to my saved trials
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated:  10/4/2017
H Lee Moffitt Cancer Cnt And Res Inst
mi
from
Tampa, FL
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated: 10/4/2017
H Lee Moffitt Cancer Cnt And Res Inst
mi
from
Tampa, FL
Click here to add this to my saved trials
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated:  10/4/2017
Oncology Specialists, SC
mi
from
Park Ridge, IL
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated: 10/4/2017
Oncology Specialists, SC
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated:  10/4/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated: 10/4/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated:  10/4/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated: 10/4/2017
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated:  10/4/2017
Nevada Cancer Center
mi
from
Las Vegas, NV
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated: 10/4/2017
Nevada Cancer Center
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated:  10/4/2017
Atlantic Melanoma Center
mi
from
Morristown, NJ
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated: 10/4/2017
Atlantic Melanoma Center
mi
from
Morristown, NJ
Click here to add this to my saved trials
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated:  10/4/2017
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated: 10/4/2017
University of New Mexico Cancer Center
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated:  10/4/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated: 10/4/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated:  10/4/2017
Levine Cancer Institute
mi
from
Charlotte, NC
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated: 10/4/2017
Levine Cancer Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated:  10/4/2017
St Luke'S Hospital And Health Network
mi
from
Bethlehem, PA
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated: 10/4/2017
St Luke'S Hospital And Health Network
mi
from
Bethlehem, PA
Click here to add this to my saved trials
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated:  10/4/2017
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated: 10/4/2017
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated:  10/4/2017
Center For Oncology Research & Treatment, P.A.
mi
from
Dallas, TX
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated: 10/4/2017
Center For Oncology Research & Treatment, P.A.
mi
from
Dallas, TX
Click here to add this to my saved trials
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated:  10/4/2017
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated: 10/4/2017
Huntsman Cancer Institute at University of Utah
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated:  10/4/2017
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated: 10/4/2017
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated:  10/4/2017
Local Institution
mi
from
Waratah,
Efficacy Study of Ipilimumab Versus Placebo to Prevent Recurrence After Complete Resection of High Risk Stage III Melanoma
Adjuvant Immunotherapy With Anti-CTLA-4 Monoclonal Antibody (Ipilimumab) Versus Placebo After Complete Resection of High Risk Stage III Melanoma: A Randomized, Double-blind Phase 3 Trial of the EORTC Melanoma Group
Status: Enrolling
Updated: 10/4/2017
Local Institution
mi
from
Waratah,
Click here to add this to my saved trials
Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread
Economic Burden of Adverse Events Associated With Follow-Up Frequency Among Patients With Metastatic Melanoma
Status: Enrolling
Updated:  10/4/2017
Bristol-Myers Squibb
mi
from
Princeton, NJ
Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread
Economic Burden of Adverse Events Associated With Follow-Up Frequency Among Patients With Metastatic Melanoma
Status: Enrolling
Updated: 10/4/2017
Bristol-Myers Squibb
mi
from
Princeton, NJ
Click here to add this to my saved trials
Skin Health Online for Melanoma: Better Risk Assessment
Personalized Genomic Testing for Skin Cancer - Maximizing Utility and Reach
Status: Enrolling
Updated:  10/5/2017
University of New Mexico
mi
from
Albuquerque, NM
Skin Health Online for Melanoma: Better Risk Assessment
Personalized Genomic Testing for Skin Cancer - Maximizing Utility and Reach
Status: Enrolling
Updated: 10/5/2017
University of New Mexico
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Promoting Early Detection of Melanoma During the Mammography Experience
Promoting Early Detection of Melanoma During the Mammography Experience
Status: Enrolling
Updated:  10/6/2017
Northwestern Memorial Hospital
mi
from
Chicago, IL
Promoting Early Detection of Melanoma During the Mammography Experience
Promoting Early Detection of Melanoma During the Mammography Experience
Status: Enrolling
Updated: 10/6/2017
Northwestern Memorial Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection
A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection
Status: Enrolling
Updated:  10/13/2017
Yale University
mi
from
New Haven, CT
A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection
A Pilot/Phase II Study of Gamma Knife Radiosurgery for Brain Metastases Using 3Tesla MRI and Rational Dose Selection
Status: Enrolling
Updated: 10/13/2017
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Study of ADI-PEG 20 in Patients With Advanced Melanoma
Phase 1/2 Study of ADI-SS PEG 20,000mw in Patients With Advanced Melanoma
Status: Enrolling
Updated:  10/19/2017
NYU Cancer Institute
mi
from
New York, NY
Study of ADI-PEG 20 in Patients With Advanced Melanoma
Phase 1/2 Study of ADI-SS PEG 20,000mw in Patients With Advanced Melanoma
Status: Enrolling
Updated: 10/19/2017
NYU Cancer Institute
mi
from
New York, NY
Click here to add this to my saved trials
Study of ADI-PEG 20 in Patients With Advanced Melanoma
Phase 1/2 Study of ADI-SS PEG 20,000mw in Patients With Advanced Melanoma
Status: Enrolling
Updated:  10/19/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Study of ADI-PEG 20 in Patients With Advanced Melanoma
Phase 1/2 Study of ADI-SS PEG 20,000mw in Patients With Advanced Melanoma
Status: Enrolling
Updated: 10/19/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials